View Post

KIYATEC Announces Addition of Capital Health as Clinical Site in Trial to Predict GBM Patient-Specific Response to Cancer Drugs Prior to Treatment

In Clinical Trials by Barbara Jacoby

Source: Capital Health From: PR Newswire KIYATEC, Inc. today announced that Capital Health has joined its U.S. clinical trial, 3D-PREDICT, to validate the company’s test as a patient-specific predictor of response to cancer therapies in glioblastoma (GBM) and anaplastic astrocytoma (AA) patients. Capital Health is currently the only healthcare system in New Jersey, Pennsylvania and the New York City region …